UniQure has submitted its gene therapy AMT-130 to the FDA for accelerated approval in Huntington’s disease — a fatal inherited neurodegenerative disorder with no treatment that slows its course.
AMT-130 is a one-time gene therapy delivered directly into the brain in an hours-long neurosurgery. In three-year data, it appeared to significantly slow signs of disease progression — a potentially historic result for a disease that has defeated drug after drug. The company filed on September 2, 2026, seeking a priority review that could yield a decision in roughly eight months, with confirmatory four-year data expected soon.
A rocky road to filing
Getting here was turbulent. Under prior FDA leadership (late 2025–mid 2026), the agency rejected UniQure’s comparison of treated patients to an external natural-history database and demanded a new sham-surgery-controlled trial — a demand that raised ethical concerns (a fake brain surgery for controls). The dispute spilled into public view; both the FDA’s then-commissioner and a top official later resigned, and by mid-2026 interim FDA leadership reversed course and accepted the original three-year dataset for filing.
Why it matters
Huntington’s is caused by a single faulty gene and progressively robs people of movement, cognition and independence. A therapy that meaningfully slows it would be a landmark — and AMT-130’s path also illustrates how much regulatory judgment (and turmoil) can shape whether such treatments reach patients. This is a filing, not an approval; the FDA’s decision is still ahead.